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Summary
Background: α1-antitrypsin (AAT) is one of the major serine proteinase inhibitors controlling
proteinases in many biological pathways. There is increasing evidence that AAT is able to exert
other than antiproteolytic effects. To further examine this question we compared how various
doses of the native (inhibitory) and the polymerised (non-inhibitory) molecular form of AAT affect
pro-inflammatory responses in human monocytes, in vitro. Human monocytes isolated from
different donors were exposed to the native or polymerised form of AAT at concentrations of
0.01, 0.02, 0.05, 0.1, 0.5 and 1 mg/ml for 18 h, and analysed to determine the release of cytokines
and to detect the activity of NF-κB.
Results: We found that native and polymerised AAT at lower concentrations, such as 0.1 mg/ml,
enhance expression of TNFα (10.9- and 4.8-fold, p < 0.001), IL-6 (22.8- and 23.4-fold, p < 0.001),
IL-8 (2.4- and 5.5-fold, p < 0.001) and MCP-1 (8.3- and 7.7-fold, p < 0.001), respectively, compared
to buffer exposed cells or cells treated with higher doses of AAT (0.5 and 1 mg/ml). In parallel to
increased cytokine levels, low concentrations of either conformation of AAT (0.02–0.1 mg/ml)
induced NF-κB p50 activation, while 1 mg/ml of either conformation of AAT suppressed the activity
of NF-κB, compared to controls.
Conclusions: The observations reported here provide further support for a central role of AAT
in inflammation, both as a regulator of proteinase activity, and as a signalling molecule for the
expression of pro-inflammatory molecules. This latter role is dependent on the concentration of
AAT, rather than on its proteinase inhibitory activity.
Background
α1-antitrypsin (AAT) is one of the major serine proteinase
inhibitors in human plasma, synthesised primarily in the
liver, but also in extra-hepatic tissues and cells, including
neutrophils, monocytes and alveolar macrophages [1-4].
Under normal conditions the daily production of AAT is
34 mg per kg body weight. The average concentration of
AAT in plasma in healthy individuals is estimated to be
1.3 mg/ml, with a half-life of 3 to 5 days [5]. The concen-
tration of AAT during acute phase processes rises by three-
to fourfold above normal while, for example, local levels
of AAT are shown to increase up to 11-fold [4]. The con-
centration of AAT in plasma also increases during oral
contraceptive therapy and pregnancy [6]. A large number
of studies has proven the importance of this rapid and
high magnitude increase in AAT concentrations for the
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local regulation of serine proteinase activity and tissue
protection against proteolytic destruction [7,8]. AAT/pro-
teinase complex formation and inhibitor inactivation pre-
sumably act as signals for inhibitor production and
turnover in the acute phase state [9]. Human neutrophils,
monocytes and alveolar macrophages can increase the
expression of AAT in response to inflammatory mediators,
such as IL-6 and endotoxins [1,7].
The distribution of AAT in tissue is not uniform, for exam-
ple, it is reduced to approximately 10% of the plasma lev-
els in the fluid of the lower respiratory tract [10], which
explains the extremely low levels of the protein in alveolar
fluid of individuals with inherited AAT deficiency. AAT
also diffuses through endothelial and epithelial cell walls
and is shown to be present in the epithelial lining fluid at
10 to 15% of total serum AAT concentration [11]. Moreo-
ver, by using a monoclonal antibody that specifically rec-
ognizes AAT polymers, we demonstrated that vascular,
endothelium-bound AAT is in a polymeric form [12].
A change of a single amino acid in certain domains of the
AAT molecule can block changes in the structure necessary
for the protein folding and normal inhibitory activity, and
can lead to the polymerization of mutant serpin [13].
Severe AAT deficiency of the homozygous PiZ phenotype,
which differs from the normal M variant in the substitu-
tion of Glu-342 by Lys, is recognized as a hereditary con-
dition predisposing to disease on the basis of low plasma
levels (10% of normal) of the protein arising not from the
lack of AAT synthesis, but from a blockage of its secretion
[14]. Polymerisation of AAT is known to be involved in
AAT deficiency-related diseases, such as liver cirrhosis,
neonatal hepatitis and hepatocellular carcinoma, which
are characterised by the formation of intracellular inclu-
sions of polymerised AAT [15-17]. Recent studies provide
evidence that AAT polymers are also present in the lungs
of emphysema patients with Z-AAT deficiency and in the
circulation of PiZ AAT carriers [12,18]. The normal M var-
iant of AAT also forms polymers in vitro, and the process
of polymer formation is shown to be dependent on tem-
perature, pH and protein concentration [19].
Individuals with homozygous PiZ AAT deficiency have
not only low baseline serum levels of AAT, but also an
attenuated acute-phase response [20]. They are particu-
larly susceptible to lung damage during bacterial exacer-
bations when there is a significant inflammatory cell
influx and a release of various proteases. Normally, all of
these proteolytic enzymes are counteracted by anti-protei-
nases, such as AAT, in amounts sufficient to prevent lung
injury. Therefore, it is widely accepted that inherited AAT
deficiency results in proteinase-antiproteinase imbalance
and that this is the proximal cause of the observed pathol-
ogies. On the other hand, while low levels of native AAT
may result in uncontrolled proteolytic activity, dysfunc-
tional forms of AAT, such as the polymerised, may have
biological activities that differ from those of native AAT at
physiological concentrations.
Various observations indicate that the native inhibitory
form of AAT exerts its effects not only by inhibiting neu-
trophil elastase and other leukocyte derived proteinases.
AAT was found to stimulate fibroblast proliferation and
procollagen synthesis [21], up-regulate human B cell dif-
ferentiation into IgE-and IgG4-secreting cells [22], interact
with the proteolytic cascade of enzymes involved in apop-
tosis [23] and to express contrasting effects on the post-
transcriptional regulation of iron between erytroid and
monocytic cells [24]. In addition, AAT can inhibit neu-
trophil superoxide production [25], induce macrophage-
derived interleukin-1 receptor antagonist release [26], and
reduce TNFα-induced lethality [27].
Together these findings lead to an idea that the develop-
ment of certain diseases might not only be ascribed to
deficiency of AAT inhibitory activity, but also other prop-
erties of this protein, realised under inflammatory condi-
tions. To address this possibility, we have tested whether
native and polymerised forms of AAT differ in vitro in their
effects on primary human monocytes, dependent on the
protein concentration used. We find that both the native
(inhibitory) and polymerised (non-inhibitory) form of
AAT have similar effects as monocyte activators, with pro-
inflammatory stimulation in low doses, and attenuation
of pro-inflammatory activities at physiologically normal
doses.
Results and discussion
AAT has been reported to influence cell function and
behaviour via both direct and indirect mechanisms
dependent on its concentration [28,29]. For example,
native AAT has been shown to stimulate and inhibit cell
proliferation, depending on cell type and the AAT concen-
tration examined [29]. Similarly, earlier studies by
Aoshiba and colleagues have shown that AAT has stimula-
tory and inhibitory effects on blood polymorphonuclear
cells migration depending on its concentration [30]. AAT
impaired chemotactic responsiveness at 2 and 10 mg/ml,
but induced chemokinesis and chemotaxis with maxi-
mum potency at 0.2 mg/ml [30]. In addition, conforma-
tionally modified molecular forms of AAT, such as
proteolytically cleaved, complexed with elastase or poly-
merised, were shown to act as potent activators and chem-
oattractants for neutrophils [31-33] and were therefore
suggested to play a role in sustaining inflammatory reac-
tions at the site of tissue injury.
In order to further investigate if AAT can express pro-and/
or anti-inflammatory effects in a dose-and conformation-BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/11
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Native and polymerised AAT (10 µg/ml) analysed by 7.5% native PAGE Figure 1
Native and polymerised AAT (10 µg/ml) analysed by 7.5% native PAGE. Lane M, molecular size markers, lane 1, native AAT and 
lane 2, polymerised AAT (incubated at 60°C, 3 h).
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Cytokines released from monocytes stimulated with various concentrations of native (A) or polymerized (B) form of AAT Figure 2
Cytokines released from monocytes stimulated with various concentrations of native (A) or polymerized (B) form of AAT. 
Each point represents the mean ± SD of six separate experiments. Significantly high up-regulation of the pro-inflammatory 
cytokines (TNF-α and IL-6) was found when cells were treated with low doses (0.05 and 0.1 mg/ml) of native or polymerized 
AAT, respectively, compared to control treated with equivalent amounts of buffer alone. The buffer control levels are indi-
cated on the graphs (TNFα in blue and IL-6 in red).
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Chemokines released from monocytes stimulated with various concentrations of native (A) or polymerized (B) form of AAT Figure 3
Chemokines released from monocytes stimulated with various concentrations of native (A) or polymerized (B) form of AAT. 
Each point represents the mean ± SD of six separate experiments. Significantly high up-regulation of the pro-inflammatory 
chemokines (IL-8 and MCP-1) was found when cells were treated with low doses (0.05 and 0.1 mg/ml) of native or polymer-
ized AAT, respectively, compared to controls treated with equivalent amounts of buffer alone. The buffer control levels are 
indicated on the graphs (MCP-1 in blue and IL-8 in red).
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dependent fashion we designed a model in which primary
human monocytes were exposed to various concentra-
tions of the native or the polymerised form of AAT for 18
h. Samples of native and polymerised AAT were subjected
to native 7.5% PAGE analysis. Fig. 1, lane 1, shows a sin-
gle molecular weight band corresponding to native AAT.
Heating of native AAT for 3 h at 60°C resulted in the gen-
eration of different size polymers of AAT (Fig. 1, lane 2).
As illustrated in Figures 2 and 3, monocytes exposed to
native or polymerised preparation of the AAT at lower
concentration (0.1 mg/ml) increase release of TNFα
(10.9- and 4.8-fold, p < 0.001), IL-6 (22.8- and 23.4-fold,
p < 0.001), IL-8 (2.4- and 5.5-fold, p < 0.001) and MCP-1
(8.3- and 7.7-fold, p < 0.001), respectively, compared to
buffer exposed cells or cells treated with higher doses of
either conformation of AAT (0.5 and 1 mg/ml). Thus, our
data provide evidence that native and polymerised AAT at
lower concentrations, i.e. 0.1 mg/ml and below, are suffi-
cient to elicit an increase in pro-inflammatory cytokine
(IL-6 and TNF-α) and chemokine (IL-8 and MCP-1)
release from monocytes in vitro, whereas the cells treated
with higher doses of either AAT manifest no activation at
all. Although low-dose AAT induced cytokine and chem-
okine release is less pronounced relative to LPS (10 ng/
ml) by approximately 10- to 100-fold (data not shown), it
is still important to point out that the observed AAT effects
are reproducible and statistically significant. In addition,
statistical comparison between relative effects of native
versus polymerised AAT (0.1 mg/ml) showed that native
AAT is significantly more potent stimulator of TNFα and
MCP-1 release, compared to polymerised AAT whereas
polymerised AAT expresses stronger effects on IL-6 and IL-
8 release (Table 1). These findings may have biological
importance and need to be further investigated.
It is known that nuclear transcription factor-κB (NF-κB)
regulates host inflammatory and immune responses and
cellular growth properties by increasing the expression of
specific cellular genes [34]. Several studies have demon-
strated that in monocytes, NF-κB activation results in the
transcription of immediate early genes that encode IL-6,
TNFα, MCP-1, as well as several other molecules [35].
Numerous stimuli are known to activate NF-κB, including
the bacterial component LPS and other pro-inflammatory
factors such as cytokines [36,37].
We have also studied the effects of native and polymerised
AAT on the expression of transcription factor NF-κB.
Monocytes exposed to native or polymerised form of AAT
at lower concentrations, such as 0.05 and 0.1 mg/ml acti-
vate NF-κB expression, compared to control, buffer-stim-
ulated cells (Figure 4), while the serum physiological level
of either AAT (1 mg/ml) down-regulates NF-κB expression
to almost undetectable level. These findings correlate with
the stimulatory effects of low dose of AAT on pro-inflam-
matory cytokine and chemokine release in monocytes
described above (Figures 2 and 3) confirming the interre-
lationship between transcription factor, NF-κB, activation
Table 1: A comparison between native (nAAT) and polymerised (pAAT) α1-antitrypsin (0.1 mg/ml) effects on cytokine and chemokine 
release.
IL-6 (pg/ml) TNFα (pg/ml)
nAAT pAAT nAAT pAAT
Mean 66.14 193.8 29.4 13.8
SD 2.6 6.04 1.2 1.8
t-value 33.7 12.5
Df 2.7 3.5
p-value <0.001 <0.001
nAAT/pAAT 2.1
pAAT/nAAT 2.9
IL-8 (pg/ml) MCP-1 (pg/ml)
nAAT pAAT nAAT pAAT
Mean 68.9 379.8 166.0 92.2
SD 0.40 10.4 27.0 3.6
t-value 51.7 4.7
Df 2.0 2.1
p-value <0.001 <0.01
nAAT/pAAT 1.8
pAAT/nAAT 5.5
Mean-values of six separate experiments SD-standard deviation, Df-degree of freedom, t-value, calculated using Walsh t test [52].BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/11
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A and B. Monitoring of NFκB p50 activation in monocytes after 18 h of exposure to different concentrations of native or  polymerized AAT by ELISA-based TransAM kitAM Figure 4
A and B. Monitoring of NFκB p50 activation in monocytes after 18 h of exposure to different concentrations of native or 
polymerized AAT by ELISA-based TransAM kitAM. Cell nuclear extracts were prepared from monocytes alone or treated with 
different concentrations of AAT. NFκB activity assay was performed in 96-well plates with 10 µg of cell extract per well. 
Absorbance was measured by spectrophotometry at 450 nm. Specificity controls were performed by adding a molar excess 
(20 pmol/well) of mutant NFκB oligonucleotide (the positive signal remained unaffected) and wild-type NFκB oligonucleotide 
(a signal was abolished). A and B represent results from two independent experiments. Each point represents the mean of two 
experiments.
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and pro-inflammatory cytokine release in response to
native and polymerised AAT.
Surprisingly, the effects of both native and polymerised
AAT on monocyte activity were parallel for all parameters
measured and at all doses, although relative effects on spe-
cific cytokine or chemokine secretion were found to be
different (Table 1). Equally important was the observation
that the cellular responses showed a marked inverse
dependence on dose, and were not dependent on the con-
formational form of AAT. Low AAT concentrations in vivo
appear to be related to a state of general AAT deficiency,
but may also reflect local depletion at different stages of
inflammation. This latter may be the evolutionary basis
for the inverse dependence on AAT concentration of the
expression of pro-inflammatory molecules. The produc-
tion of cytokines, chemokines, cell surface receptor/adhe-
sion proteins, and other molecules by activated
monocytes, macrophages and neutrophils can serve to
orchestrate the immune response and is essential to host
defence. The increased expression of a defined set of
cytokines, such as IL-6 and TNFα, is believed to be one of
the major pathological mediators of inflammatory dis-
eases. Chemotactic cytokines (chemokines) are also gen-
erated locally, and this stimulates monocytes to migrate
into the site of inflammation. In particular, IL-8 and MCP-
1 have been implicated in diseases characterised by
monocyte-rich infiltrates because of its ability to induce
monocyte trafficking and activation [38]. IL-6, TNFα, IL-8
and MCP-1 are all hallmarks of inflammation and sustain
the multiple inflammation-associated processes of lym-
phocyte attraction, differentiation, immunoglobulin
secretion, primary monocyte recruitment, neutrophil
attraction and up-regulation of extracellular matrix-
degrading properties [39]. They are all most likely regu-
lated by genes controlled from the NF-κB promoter, since
their expression correlates strongly with NF-κB activation
in our monocyte stimulation model. Based on our results,
it is very likely that at low concentrations native as well as
polymerised AAT may contribute to inflammatory events
in vivo.
The inverse dependence on AAT concentration observed
for the expression of pro-inflammatory reactance suggests
a possible receptor-dependent feedback loop in which
AAT is the key ligand. The cellular receptor for AAT has not
been identified to date, although the cell surface receptors,
termed serpin-enzyme complex (SEC) receptor [9], low
density lipoprotein related (LRP) receptor [40], low den-
sity lipoprotein (LDL) receptor [41] and very low density
lipoprotein (VLDL) receptor [42] which bind AAT- and
other serpin-enzyme complexes and are involved in its
internalisation and degradation, have been described. It is
also known that AAT biosynthesis is responsive to levels
of pro-inflammatory cytokines and to levels of inactivated
forms of AAT through their uptake at the SEC receptor
[7,9,43]. A parallel feedback loop may exist for inhibitory-
active AAT, and as we show here for the polymerised form
of AAT, in which rising levels of these molecular forms are
signals for a plateau in inflammation. By saturating a
receptor(s), these forms of AAT at increasing concentra-
tions may signal down-regulation of the expression of
pro-inflammatory reactants, i.e. a pro-inflammatory role
of AAT at low concentrations can be linked to the phe-
nomenon of partial agonism [44].
The observations reported here provide further support
for a central role of AAT in inflammation, both as a regu-
lator of protease activity and as a signalling molecule. The
fact that polymerised AAT has parallel effects to native
AAT suggests a putative common receptor acting as a sen-
sor for rising levels of un-reacted, non-degraded molecu-
lar forms of AAT. This idea is partially supported by our
earlier studies showing that low doses of oxidised (non-
inhibitory) form of AAT induce pro-inflammatory mono-
cyte activation in vitro [45].
Conclusions
Here we show that AAT may play multiple roles at sites of
inflammation, which may be determined not only by the
conformational modifications of AAT, but also directly by
the reduction in its concentration. It is well established
that native AAT is the most abundant circulating protein-
ase inhibitor, which is responsible for the regulation of
proteolytic enzymes and the maintenance of homeostasis
in humans. A substantial number of pathological
problems are suggested to result from any mechanism
causing the reduction in the levels of the inhibitory active
form of AAT, including inactivation by non-target protei-
nases, oxidative inactivation, polymerisation, or genetic
aberrations in structure [46-48]. Our data show that at
low concentrations (at approximately 10% of normal)
AAT exerts direct pro-inflammatory effects in human
monocytes, leading to the hypothesis that inherited and/
or acquired AAT deficiency in itself may be a consequence
of the development of chronic inflammatory processes. It
also explains the greater susceptibility of individuals with
severe Z-AAT deficiency to develop chronic inflammatory
processes. Therefore, a marked increase in AAT concentra-
tion (from 4 to 5-fold and locally up to 11-fold) during
acute inflammatory reactions appears to be an anti-
inflammatory condition, and the further investigation of
it may provide a new target for the development of thera-
peutic agents to regulate inflammation.
Methods
Specific reagents
Human plasma AAT (purity > 95%, and inhibitory activity
> 75%) was obtained from Calbiochem, USA and from
Clinical chemistry laboratory, University HospitalBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/11
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Malmo, Sweden. Native AAT was diluted in PBS, pH 7.4,
and, to ensure the complete removal of endotoxins, was
decontaminated using endotoxin removing gel (Detoxi-
Gel columns, Pierce, USA). AAT polymers were prepared
as described previously [49] by incubating native AAT
(final concentration 1 mg/ml) at 60°C for 3 h with gentle
shaking. Polymer formation was confirmed by non-dena-
turing 7.5% PAGE and a concomitant loss of inhibitory
activity against pancreatic elastase. The AAT-polymer mix-
ture was reheated as necessary to ensure that the polymers
were not contaminated with monomeric AAT. Protein
preparations used in all assays were assayed for endotox-
ins using the LAL, Lumulus Amebocyte Lysate, Endo-
chrome™ test (Sigma Chemical company, USA). In all
samples of native and polymerized AAT used in the subse-
quent experiments endotoxin levels were less than 0.3
EU/mg of protein.
Isolation and culture of monocytes
Human monocytes were isolated from buffy coats from
different donors by the Ficoll-Hypaque procedure as pre-
viously detailed [50]. Cell purity was > 97% as determined
on an AC900EO AutoCounter (Swelab Instruments, AB);
cell viability was analysed by staining with 0.4 % trypan
blue. Monocytes were plated at a density of 4 × 106 cells/
ml into plastic dishes. After removal of non-adhering
cells, the remaining adherent monocytes were cultured in
RPMI 1640 (Gibco, Life Technologies, Paisley, Scotland)
supplemented with 2 mM N-acetyl-L-alanyl-L-glutamine,
100 U/ml penicillin, 100 µg/ml streptomycin, 1% non-
essential amino acid, 2% sodium pyruvate and 20 mM
Hepes (Fluka, Chemie AG) without serum at 37°C in an
atmosphere of 5% CO2. Monocytes were treated with
native or polymerised AAT at concentrations of 0.01, 0.02,
0.05, 0.1, 0.5 and 1 mg/ml for 18 h. Control wells con-
tained the same volumes of PBS or were incubated in
medium alone. At the end of the incubations cell-free
supernatants were collected and stored at -20°C until
analysis. It must be pointed out that no difference was
observed between control cells alone and treated with PBS
therefore all presented data are calculated from the buffer
controls. Each experiment was done at a minimum in trip-
licate for each condition.
Cytokine and chemokine asssys
Cell culture supernatants from monocytes treated with
various concentrations of native and polymerised AAT
were analysed to determine TNF-α, IL-6, IL-8 and MCP-1
by using sandwich DuoSet ELISA kits according to the
manufacturer's instructions (R&D Systems, England). The
detection limits for the assays were as follows: IL-8, 15.6
pg/ml, MCP-1, 7.8 pg/ml, TNF-α, 7.8 pg/ml, IL-6, 2.3 pg/
ml.
Nuclear extract preparation and NFκB activation 
monitoring assay
Nuclear extracts from monocytes were prepared exclu-
sively as described previously [51]. Protein concentrations
were determined spectrophotometrically at 260 nm and
using the Comassie Plus protein assay reagent according
to instructions from the manufacturer (Pierce, IL, USA).
NF-κB in nuclear extracts were analysed using TransAm
kits (Activemotif, CA, USA) specific for p50 subunit
according to manufactures instructions. Detection limit
<0.5 µg cell extract per well.
Statistical analysis
The differences in the means in experimental results were
analysed for their statistical significance by one-way anal-
ysis of variance (ANOVA) combined with a multiple com-
parisons procedure (Scheffé multiple range test) with the
overall significance level of α = 0.05. The Statistical Pack-
age for Social Sciences (SPSS for Windows, release 11.0)
was used for the calculations.
Abbreviations
AAT, alpha1-antitrypsin, PiZZ, homozygous type Z defi-
ciency variant; PiMM, normal AAT gene variant; MCP-1,
monocyte chemoattractant protein-1; TNFα, tumour
necrosis factor-α; IL, interleukin, PBS, phosphate buffered
saline; NF-κB, nuclear factor-κB, Ig, immunoglobulin;
PAGE, polyacrylamide gel electrophoresis; LPS, lipopoly-
sacharide; SEC, serpin-enzyme complex; LRP, low density
lipoprotein related protein; LDL, low density lipoprotein;
VLDL, very low density lipoprotein.
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